News
08-02-2010, 05:50 AM
BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.
More... (http://www.news-medical.net/news/20100802/Phase-III-clinical-study-data-of-OncoVEXGM-CSF-for-head-and-neck-cancer-published-in-Clinical-Cancer-Research.aspx)
More... (http://www.news-medical.net/news/20100802/Phase-III-clinical-study-data-of-OncoVEXGM-CSF-for-head-and-neck-cancer-published-in-Clinical-Cancer-Research.aspx)